Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Mammoth Biosciences Inc. currently faces 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 5 actions are spread across 5 distinct examiners, which indicates that no pending matters are currently before the same individual. The prosecution is active across 4 distinct art units, suggesting that the company's biotechnology research is being evaluated by several different specialized units at the patent office. This variety across 4 distinct art units highlights the technical breadth of the 5 pending office actions.
The busiest examiner for this portfolio is MATALKAH, FATIMAH KHALAF, who is responsible for 1 pending office action. Since there are 5 distinct examiners for the 5 pending office actions, the workload is decentralized among the patent office staff. This distribution requires the company to manage 5 separate examiner relationships across 4 distinct art units, with no single examiner handling a majority of the pending biotechnology applications. Each of the 5 pending office actions represents a unique examiner interaction.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MATALKAH, FATIMAH KHALAF | 1 | 54.8% | +28.6% |
| LEONARD, ARTHUR S | 1 | 50.8% | +50.2% |
| VANN-OJUEKAIYE, KENDRA RAYCHELL | 1 | 0.0% | +0.0% |
| DIBRINO, MARIANNE | 1 | 42.8% | +42.2% |
| JONES, CHRISTINE MICHELLE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18334327 | METHODS AND COMPOSITIONS FOR PERFORMING A DETECTION ASSAY | VANN-OJUEKAIYE, KENDRA RAYCHELL | 34d |
| 17687498 | PROGRAMMABLE NUCLEASE COMPOSITIONS AND METHODS OF USE THEREOF | DIBRINO, MARIANNE | 70d |
| 18413896 | VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF | MATALKAH, FATIMAH KHALAF | — |
| 17495652 | PROGRAMMABLE NUCLEASE IMPROVEMENTS AND COMPOSITIONS AND METHODS FOR NUCLEIC ACID AMPLIFICATION AND DETECTION | JONES, CHRISTINE MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17687498 | PROGRAMMABLE NUCLEASE COMPOSITIONS AND METHODS OF USE THEREOF | DIBRINO, MARIANNE | 70d |
| 18413896 | VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF | MATALKAH, FATIMAH KHALAF | — |
| 18528523 | EFFECTOR PROTEINS AND METHODS OF USE | LEONARD, ARTHUR S | — |
| Art Unit | Apps |
|---|---|
| 1682 | 2 |
| 1638 | 1 |
| 1631 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18413896 | VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF | MATALKAH, FATIMAH KHALAF | 1638 | §102§103 | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18528523 | EFFECTOR PROTEINS AND METHODS OF USE | LEONARD, ARTHUR S | 1631 | §112DP | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18334327 | METHODS AND COMPOSITIONS FOR PERFORMING A DETECTION ASSAY | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103Other | Non-Final OA | 34d | Pending | Jun 13, 2023 |
| 17687498 | PROGRAMMABLE NUCLEASE COMPOSITIONS AND METHODS OF USE THEREOF | DIBRINO, MARIANNE | 1641 | §102§103Other | Non-Final OA | 70d | Pending | Mar 04, 2022 |
| 17495652 | PROGRAMMABLE NUCLEASE IMPROVEMENTS AND COMPOSITIONS AND METHODS FOR NUCLEIC ACID AMPLIFICATION AND DETECTION | JONES, CHRISTINE MICHELLE | 1682 | DP | Final Rejection | — | Pending | Oct 06, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial